Markus Hinder

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications

Reassessing R&D outcomes of leading pharmaceutical companies.

Reassessing R&D outcomes of leading pharmaceutical companies.

Journal: Drug discovery today
Published: May 29, 2026

Letter to the Editor of the British Journal of Clinical Pharmacology Re: van Iersel et al. (2026)-Why do healthy volunteers participate in clinical trials? doi: https://doi.org/10.1002/bcp.70499.

Letter to the Editor of the British Journal of Clinical Pharmacology Re: van Iersel et al. (2026)-Why do healthy volunteers participate in clinical trials? doi: https://doi.org/10.1002/bcp.70499.

Journal: British journal of clinical pharmacology
Published: April 10, 2026

A Phase 2 (2a) Randomized Trial of Iscalimab in Adolescents and Young Adults with New-Onset Type 1 Diabetes.

A Phase 2 (2a) Randomized Trial of Iscalimab in Adolescents and Young Adults with New-Onset Type 1 Diabetes.

Journal: Diabetes technology & therapeutics
Published: November 28, 2025

New perspectives for better R&D performance: lessons learned from leading pharma companies.

New perspectives for better R&D performance: lessons learned from leading pharma companies.

Journal: Drug discovery today
Published: October 30, 2025

The Role of Data Monitoring Committees in drug research.

The Role of Data Monitoring Committees in drug research.

Journal: Drug discovery today
Published: August 22, 2025

Letter to the editor of the Brit J Clin Pharmacol on Heuberger et al. 2025 https://doi.org/10.1002/bcp.70090.

Letter to the editor of the Brit J Clin Pharmacol on Heuberger et al. 2025 https://doi.org/10.1002/bcp.70090.

Journal: British journal of clinical pharmacology
Published: June 06, 2025

Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study.

Blood Pressure Lowering Effects of a Novel Long-Acting NPR1 Agonist, XXB750, in Healthy Participants: A Randomized, First-in-Human Clinical Study.

Journal: Circulation
Published: May 27, 2025

The R&D productivity challenge: transforming the pharmaceutical ecosystem.

The R&D productivity challenge: transforming the pharmaceutical ecosystem.

Journal: Drug discovery today
Published: May 13, 2025

Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.

Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies.

Journal: Lancet (London, England)
Published: March 21, 2025

Corrigendum to "Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)" [Drug Discov. Today 30(2) (2025) 104291].

Corrigendum to "Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)" [Drug Discov. Today 30(2) (2025) 104291].

Journal: Drug discovery today
Published: March 13, 2025

A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies.

A case study assessing the impact of M&A and licensing on FDA drug approvals of leading pharmaceutical companies.

Journal: Drug discovery today
Published: November 22, 2024

Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022).

Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022).

Journal: Drug discovery today
Published: October 21, 2024
Showing 1-12 of 42

Last Updated: 09/26/2026